You are here

  • Home
  • Online First
  • Is incentivising stroke prevention therapy in atrial fibrillation the key?

Article Text

Article menu

other Versions

Download PDFPDF
Editorial
Is incentivising stroke prevention therapy in atrial fibrillation the key?
  1. Roopinder K Sandhu,
  2. Justin A Ezekowitz
  1. Department of Cardiology, University of Alberta, Edmonton, Alberta, Canada
  1. Correspondence to Dr Justin A Ezekowitz, Department of Cardiology, University of Alberta, Edmonton, AB T6G 2B7, Canada; jae2{at}ualberta.ca

https://doi.org/10.1136/heartjnl-2018-313402

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Atrial fibrillation (AF) is a condition of global importance with significant and progressive effects on morbidity, mortality and healthcare expenditure.1 The prevalence of AF is rising, and it is projected to at least double over the next 30 years due to advancing age and increasing risk factors for developing AF including cardiovascular illness and adverse lifestyle factors. AF is the leading cause of stroke, and by comparison to other types of stroke,2 AF-related stroke is more severe; yet highly preventable. Although we have overwhelming evidence that oral anticoagulation (OAC) is highly effective in preventing stroke in patients with AF,3 therapy has remained underused until recently.

    In their Heart paper, Adderley et al 4 report the results of temporal trends in age-sex standardised AF prevalence and use of stroke prevention therapy among 744 primary care practices across the UK from 2000 to 2016. Once again, this demonstrates the value of high-quality (and very large) data sets utilising data from a practice rather than a hospital level, the authors are able to characterise over 5 million individuals with AF. Seventeen sequential …

    View Full Text

    Footnotes

    • Contributors RKS wrote the first draft of the editorial, and both authors edited the overall manuscript.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests JAE has received research support and honoraria from BMS/Pfizer and Bayer related to oral anticoagulation in patients with atrial fibrillation and served on the Steering Committee for ARISTOTLE. RKS has no relevant disclosures.

    • Patient consent Not required.

    • Provenance and peer review Commissioned; internally peer reviewed.

    Linked Articles